IP Library Granted Patent US 9,220,681
Granted Patent B2
US 9,220,681 · App. 13/935,859 · Granted Dec 29, 2015

Formulations

Inventors: Ivan Coulter (County Dublin, IE); Bernard Francis McDonald (County Monaghan, IE); Vincenzo Aversa (County Dublin, IE); Mónica Rosa (Dublin, IE)
Assignee: Sigmoid Pharma Limited
A61K9/06A61K9/146A61K9/5073A61K9/5161A61K39/0002A61K39/0208A61K39/0258A61K39/107A61K39/12A61K39/39A61K47/36A61K2039/52A61K2039/54A61K2039/542A61K2039/55511
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,220,681
App. No.
13/935,859
Granted
Dec 29, 2015
Kind
B2
Abstract

This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. beads, comprising a matrix material which matrix material comprises a microorganism. In particular, the invention relates to compositions comprising a microorganism selected from live, killed, attenuated and inactivated microorganisms. The matrix material may also comprise a surfactant and may further comprise an adjuvant. The invention further relates to the manufacture and use of such compositions, and to other subject matter.

Claims (56)

1. A composition comprising

a surfactant selected from a polyethoxylated hydroxy fatty acid; a microorganism selected from live, killed, attenuated and inactivated microorganisms, wherein the microorganism is a bacterium selected from the group consisting of enterotoxigenic E. coli, Helicobacter pylori, Clostridium difficile, Shigella sonnei, Shigella boydii, Shigella dysenteriae and Shigella flexneri;

a glycolipid adjuvant, and

a matrix comprising a hydrogel-forming polymer in which the surfactant, the microorganism and the adjuvant are included, wherein the hydrogel-forming polymer is selected from the group consisting of gelatin, agar, agarose, pectin, carrageenan, and chitosan, and combinations thereof;

and wherein the composition when combined with water is capable of releasing self-assembly structures comprising surfactant and adjuvant.

2. The composition of claim 1 wherein at least a portion of the adjuvant is associated with at least a portion of the surfactant.

3. The composition of claim 1 wherein at least a portion of the microorganism content is associated with at least a portion of the surfactant.

4. The composition of claim 1 wherein the weight ratio of said surfactant to the hydrogel-forming polymer is from 1:0.5 to 1:2.5.

5. The composition of claim 4 wherein the weight ratio of said surfactant to the hydrogel-forming polymer is from 1:1.4 to 1:1.8.

6. The composition of claim 1 wherein the hydrogel-forming polymer comprises, or is, gelatin.

7. The composition of claim 1 comprising chitosan.

8. The composition of claim 1 wherein the bacterium is enterotoxigenic E. coli.

9. The composition of claim 1 wherein the bacterium is Helicobacter pylori.

10. The composition of claim 1 which further comprises one or more antigens additional to the microorganism.

11. A composition of claim 1 wherein the adjuvant is, or comprises, an immunostimulator.

12. The composition of claim 11 wherein the immunostimulator is a T-cell activator or an activator, of an antigen-presenting cell or other immune cell.

13. The composition of claim 11 wherein the adjuvant is, or comprises, a ceramide.

14. The composition of claim 1 wherein the microorganism consists of one or more unicellular microorganisms and the ratio of adjuvant to the aggregate amount of unicellular microorganisms (mg dry weight of adjuvant to 10^10 cells) is from 0.1-100 mg:10^10 cells.

15. The composition of claim 1 wherein the surfactant comprises an alkyl chain which is unsubstituted or is substituted by a single hydroxy group.

16. The composition of claim 1 wherein the surfactant is macrogol-15-hydroxystearate.

17. The composition of claim 1 which further comprises a cationic lipid.

18. The composition of claim 1 wherein the microorganism consists of one or more unicellular microorganisms and the ratio of surfactant to the aggregate amount of unicellular microorganisms (mg dry weight of surfactant to 10^10 cells) is from 10-200 mg:10^10 cells.

19. The composition of claim 1 which is in the form of a bead having a diameter of from 0.5 mm to 5 mm.

20. The composition of claim 19 wherein the bead has a diameter of from 1 mm to 2 mm.

21. The composition of claim 19 wherein the hydrogel-forming polymer is substantially dry and wherein the bead has a coating.

22. The composition of claim 21 wherein the coating comprises an active ingredient.

23. The composition of claim 21 wherein the coating is an immediate release coating.

24. The composition of claim 21 wherein the bead comprises a controlled release coating.

25. The composition of claim 1 which further comprises an immune-enhancing nutrient.

26. The composition of claim 1 wherein the microorganism comprises, or is, a combination of intact and fragmented microorganism cells.

27. An oral dosage form comprising a population of beads of claim 19 .

28. The dosage form of claim 27 comprising a first population of said beads and a second population of said beads different from those of the first population.

29. The composition of claim 1 wherein the weight ratio of said surfactant to the hydrogel-forming polymer is from 1:0.5 to 1:2.

30. The composition of claim 1 wherein the weight ratio of said surfactant to the hydrogel-forming polymer is from 1:1.6 to 1:1.7.

31. The composition according to claim 1 wherein the adjuvant is α-galactosylceramide.

32. The composition of claim 2 wherein the microorganism consists of one or more unicellular microorganisms and the ratio of adjuvant to the aggregate amount of unicellular microorganisms (mg dry weight of adjuvant to 10^10 cells) is from 0.4-5 mg:10^ 10 cells.

33. The composition of claim 1 wherein the surfactant is, or comprises, a PEGylated hydroxy fatty acid in combination with free PEG.

34. The composition of claim 21 wherein the bead comprises an enteric coating.

35. The composition of claim 1 wherein the composition is for oral administration.

36. The composition of claim 1 which further comprises a cationic lipid selected from DOTAP (N-[1-(2,3-dioleoyloxy)]-N,N,N-trimethylammonium propane methylsulfate) and DOSPER (1,3-dioleoyloxy-2-(6-carboxyspermyl)-propyl amide).

37. The composition of claim 1 wherein the microorganism is formalin-killed.

38. The composition of claim 1 wherein the wherein the glycolipid is dissolved in the surfactant.

39. A composition comprising

a surfactant comprising a macrogol-15-hydroxystearate, a microorganism selected from live, killed, attenuated and inactivated microorganisms, wherein the microorganism is a bacterium selected from the group consisting of enterotoxigenic E. coli, Helicobacter pylori, Clostridium difficile, Shiaella sonnei, Shigella boydii, Shigella dysenteriae and Shiaella flexneri;

an adjuvant comprising α-GalCer, and

a hydrogel-forming polymer in which the surfactant, the microorganism and the adjuvant, α-GalCer, are included, wherein the hydrogel-forming polymer is selected from the group consisting of gelatin, agar, agarose, pectin, carrageenan, and chitosan, and combinations thereof;

and wherein the composition when combined with water is capable of releasing self-assembly structures.

40. The composition of claim 39 , wherein the microorganism is ETEC.

41. The composition of claim 25 , wherein the nutrient is one or more nutrients selected from vitamin A, vitamin B, vitamin C, vitamin E, carotenoids, iron, manganese, selenium and zinc.

42. The composition of claim 41 , wherein the vitamin B is selected from vitamin B6, vitamin B12, niacin (vitamin B3), pantothenic acid, riboflavin (vitamin B2), thiamin (vitamin B1) or folic acid.

43. The composition of claim 1 wherein the microorganism is Clostridium difficile.

44. The composition of claim 39 wherein the microorganism is Helicobacter pylori.

45. The composition of claim 39 wherein the microorganism is Clostridium difficile.

46. The composition of claim 39 wherein the hydrogel-forming polymer is gelatin.

47. The composition of claim 1 , wherein the microorganism is selected from the group consisting of Shigella sonnei, Shigella boydii, Shigella dysenteriae, and Shigella flexneri.

48. The composition of claim 39 , wherein the microorganism is selected from the group consisting of Shigella sonnei, Shigella boydii, Shigella dysenteriae and Shigella flexneri.

Assignments (2)
CHANGE OF NAME Recorded Dec 11, 2018
From: SIGMOID PHARMA LIMITED
To: SUBLIMITY THERAPEUTICS LIMITED
Reel/Frame 047748/0327 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2013
From: COULTER, IVAN; MCDONALD, BERNARD FRANCIS; AVERSA, VINCENZO; ROSA, MONICA
To: SIGMOID PHARMA LIMITED
Reel/Frame 031315/0219 →
Priority Claims (1)
GB 1212010.1 · Jul 5, 2012 · national
Continuity (2)
Provisional Application 61782066 · Mar 14, 2013
Related Publication 20140017313A1 · Jan 16, 2014